TGFB1 and neoplasm: Components such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated fibroblasts (CAFs), and immunosuppressive cytokines like TGF-β and IL-10 create an inhibitory milieu that limits CAR-T efficacy [36].